Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/Oncologysierra health and life Reblozyl Coverage Update | …
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0084L

    Reblozyl (Luspatercept-Aamt) coverage

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0084L alerts

    Get alerted when Policy 2026D0084L changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and authorization criteria for Reblozyl (luspatercept-aamt) for UnitedHealthcare Commercial and Individual Exchange benefit plans, covering specific hematologic indications in adults.

    Policy Summary
    Payersierra health and life
    PolicyReblozyl (Luspatercept-Aamt) coverage
    Policy CodePolicy 2026D0084L
    Change TypeClinical content and references updatedtemplate and application details revised
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of indication, specialist involvement, dosing per FDA labeling, and evidence of clinical response for continuation requests.
    SourceLink
    POLICY UPDATE CHANGES

    Template updated and content transferred to a shared policy template; Application section added specifying that the policy applies to UnitedHealthcare Commercial and Individual Exchange benefit plans.

    Background, Clinical Evidence, and References sections updated to reflect the most current information.

    12 monthsmax approval period
    ≥6min PRBCs (24 wks)
    35 daysmax transfusion-free interval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≤500
    EPO threshold
    J0896HCPCS
    3FDA indications

    Coverage Criteria for Reblozyl (luspatercept-aamt)

    Initial Therapy — Beta thalassemia

    Covered when ALL of the following are met

    Beta thalassemia initial: Diagnosis of anemia due to beta thalassemia (including beta+ thalassemia, beta0 thalassemia, and hemoglobin E/beta thalassemia); patient is ≥ 18 years of age; patient is transfusion dependent as evidenced in the previous 24 weeks by BOTH: has required at least six units of packed red blood cells (PRBC) AND no transfusion-free period greater than 35 days; prescribed by, or in consultation with, a hematologist or other specialist with expertise in the diagnosis and management of beta thalassemia; dosing in accordance with FDA-approved labeling; initial authorization for no more than 12 months

    Continuation Therapy — Beta thalassemia

    Covered when ALL of the following are met

    Beta thalassemia continuation: Documentation of a positive clinical response to Reblozyl (e.g., reduction in transfusion burden or increase in hemoglobin from baseline); prescribed by, or in consultation with, a hematologist or other specialist with expertise in the diagnosis and management of beta thalassemia; dosing in accordance with FDA-approved labeling; reauthorization for no more than 12 months

    Initial Therapy — Myelodysplastic Syndromes (MDS)

    Covered when ALL of the following are met

    MDS initial

    • Option A: Both: ring sideroblasts < 15% (or <5% with SF3B1 mutation) AND serum erythropoietin ≤ 500 mU/mL
    • Option B: Ring sideroblasts ≥ 15% (or ≥5% with SF3B1 mutation)

    Continuation Therapy — MDS

    Covered when ALL of the following are met

    MDS continuation: Documentation of a positive clinical response to Reblozyl (e.g., reduction in transfusion burden or increase in hemoglobin from baseline); prescribed by, or in consultation with, a hematologist/oncologist or other specialist with expertise in MDS; dosing in accordance with FDA-approved labeling; reauthorization for no more than 12 months

    Initial Therapy — MDS/MPN overlap

    Covered when ALL of the following are met

    MDS/MPN initial: Diagnosis of anemia due to MDS/MPN; presence of an SF3B1 mutation; thrombocytosis defined as platelet count ≥ 450 x 10^9/L; prescribed by, or in consultation with, a hematologist/oncologist or other specialist with expertise in MDS/MPN; dosing in accordance with FDA-approved labeling; initial authorization for no more than 12 months

    Continuation Therapy — MDS/MPN overlap

    Covered when ALL of the following are met

    MDS/MPN continuation: Documentation of a positive clinical response to Reblozyl (e.g., reduction in transfusion burden or increase in hemoglobin from baseline); prescribed by, or in consultation with, a hematologist/oncologist or other specialist with expertise in MDS/MPN; dosing in accordance with FDA-approved labeling; reauthorization for no more than 12 months

    Initial Therapy — Myelofibrosis-associated anemia

    Covered when ALL of the following are met

    Myelofibrosis initial

    • Option A: Both: symptomatic splenomegaly and/or constitutional symptoms AND used in combination with a JAK inhibitor (examples: fedratinib, ruxolitinib, momelotinib, pacritinib)
    • Option B: No splenomegaly or constitutional symptoms

    Continuation Therapy — Myelofibrosis-associated anemia

    Covered when ALL of the following are met

    Myelofibrosis continuation: Documentation of a positive clinical response to Reblozyl (e.g., reduction in transfusion burden or increase in hemoglobin from baseline); Reblozyl is prescribed by, or in consultation with, a hematologist/oncologist or other specialist with expertise in myelofibrosis; dosing is in accordance with FDA-approved labeling; reauthorization for no more than 12 months

    Continuation Therapy — Continuation of Therapy

    Continuation of Therapy

    Continuation criteria for Reblozyl: Documentation of a positive clinical response (e.g., reduction in transfusion burden, increase in hemoglobin from baseline); Reblozyl is prescribed by, or in consultation with, a hematologist, oncologist, or other specialist with expertise in the diagnosis and management of the relevant condition; dosing is in accordance with FDA-approved labeling; reauthorization will be for no more than 12 months

    Applies to continuation/reauthorization only

    FDA Indications

    FDA-Indicated Uses (informational; approval alone not basis for coverage)

    FDA Indications: Anemia in adult patients with beta thalassemia who require regular RBC transfusions; anemia without previous erythropoiesis-stimulating agent use in adult patients with very low- to intermediate-risk MDS who may require regular RBC transfusions; anemia failing an ESA and requiring ≥2 RBC units over 8 weeks in adult patients with very low- to intermediate-risk MDS with ring sideroblasts or with MDS/MPN-RS-T. Limitations of use: not a substitute for immediate RBC transfusions.

    Informational only; FDA approval alone is not a basis for coverage

    Compendia-based recommendations

    NCCN recommended uses (informational)

    NCCN recommendations: Treatment of lower-risk MDS associated with symptomatic anemia and no del(5q) with ring sideroblasts ≥15% (or ≥5% with SF3B1 mutation); treatment of lower-risk MDS with ring sideroblasts <15% (or <5% with SF3B1 mutation) and serum erythropoietin ≤500 mU/mL; management of myelofibrosis-associated anemia including use with JAK inhibitors; treatment of MDS/MPN with SF3B1 mutation and thrombocytosis.

    NCCN defines lack of response as <1.5 g/dL hemoglobin rise or no decrease in transfusion requirement by 6–8 weeks

    Reblozyl (luspatercept‑aamt) is not proven or medically necessary for the treatment of the following conditions: alpha thalassemia, beta thalassemia in pediatric patients, non‑transfusion dependent beta thalassemia, and sickle beta thalassemia (HbS/beta thalassemia). Requests for coverage for these diagnoses may be denied.

    In addition, UnitedHealthcare follows the NCCN Drugs and Biologics Compendium framework: indications with NCCN Categories of Evidence and Consensus of 3 are considered unproven and not medically necessary. Use of Reblozyl for any indication classified as Category 3 by NCCN is therefore considered not covered.

    Providers should not submit authorization requests for the conditions listed above as medically necessary uses. When a requested indication corresponds to an NCCN Category 3 recommendation, coverage is not supported. Documentation submitted for these indications will be reviewed but is likely to result in a denial based on the policy’s stated exclusions.

    Specifically, use of Reblozyl for the listed thalassemia subtypes and for pediatric beta thalassemia is considered not medically necessary. Prior authorization requests for these populations are expected to be excluded from coverage under this policy.

    Coding and Diagnostic References

    Covered/Reference HCPCSHCPCS
    J0896Injection, luspatercept-aamt, 0.25 mg.
    Relevant ICD-10 Codes (reference)ICD-10
    D46.1Refractory anemia with ring sideroblasts.
    D46.20Refractory anemia with excess of blasts, unspecified.
    D46.21Refractory anemia with excess of blasts 1.
    D46.22Refractory anemia with excess of blasts 2.
    D46.BRefractory cytopenia with multilineage dysplasia and ring sideroblasts.
    D56.1Beta thalassemia.
    D56.5Hemoglobin E-beta thalassemia.
    Transfusion history — Inv-18
    ThresholdAt least six units of packed red blood cells (PRBC) in the prior 24 weeks
    Maximum transfusion‑free intervalNo transfusion‑free period greater than 35 days within the prior 24 weeks
    ContextUsed to define transfusion‑dependent beta thalassemia for initial eligibility and continuation criteria
    Serum erythropoietin — Inv-19
    Serum erythropoietin threshold≤ 500 mU/mL
    Use caseRequired for selection of some lower‑risk MDS patients when ring sideroblasts are below threshold

    Provider Requirements, Documentation, and Prior Authorization

    Prior Authorization

    Authorization duration and renewal

    Prior authorization is required for initial and continuation/reauthorization requests. Initial approvals and any reauthorization will be for no more than 12 months.

    • Initial authorization will be for no more than 12 months.
    • Reauthorization will be for no more than 12 months.
    Prior Authorization

    Prior authorization and reauthorization — required documentation

    Obtain prior authorization and include documentation of the clinical indication, the member’s response for continuation requests, that the drug is prescribed by or in consultation with an appropriate specialist, and that dosing follows FDA‑approved labeling.

    • Document the indication (diagnosis meeting the policy criteria).
    • For continuation/reauthorization, provide evidence of positive clinical response (see continuation documentation requirements).
    • Confirm prescribing clinician is a hematologist/oncologist or specialist experienced in the relevant disease and that dosing is per FDA labeling.

    Background and Clinical Context

    Reblozyl (luspatercept‑aamt) is an erythroid maturation agent indicated to treat anemia in certain hematologic disorders. This policy clarifies that, despite FDA and compendia statements for specific adult indications, Reblozyl is not covered for the thalassemia subtypes and pediatric beta thalassemia listed above and follows NCCN categorizations when determining whether compendia recommendations constitute proven, medically necessary uses.

    Definitions and Key Terms

    Transfusion dependent beta thalassemia — Inv-32
    Transfusion threshold (policy definition)Requirement of at least six units PRBC in the prior 24 weeks
    Maximum transfusion‑free intervalNo transfusion‑free period greater than 35 days within that 24‑week period
    Applicable populationDefines transfusion‑dependent beta thalassemia for adult eligibility (age ≥18) under coverage criteria
    Lower risk MDS — Inv-33
    Lower‑risk definition (IPSS‑R)IPSS‑R categories Very Low, Low, or Intermediate
    Ring sideroblast/EPO considerationsEligibility depends on ring sideroblast percentage and serum erythropoietin (e.g., RS <15% requires EPO ≤ 500 mU/mL; RS ≥15% qualifies independently)

    Line of Therapy and Treatment Positioning

    informational

    Clinical evidence note: NCCN defines a lack of response to luspatercept as a lack of 1.5 g/dL rise in hemoglobin or lack of a decrease in RBC transfusion requirement by 6 to 8 weeks of treatment.

    Informational

    first-line | second-line

    Line/context: Used in ESA-naive lower-risk MDS patients who may require RBC transfusions and in patients who failed ESA therapy; used for anemia in transfusion-dependent beta thalassemia adults; used for management of myelofibrosis-associated anemia in combination with JAK inhibitors per NCCN; document prior ESA exposure status for MDS indications.

    Informational

    Biomarker and Laboratory Requirements

    SF3B1 — Inv-38
    BiomarkerSF3B1 mutation mentioned as required for MDS/MPN overlap eligibility
    Clinical relevanceSF3B1 status used to interpret ring sideroblast percentages and to define MDS/MPN cases eligible for therapy
    Source detailReferenced in coverage criteria and NCCN recommendations
    SF3B1 — Inv-39
    Ring sideroblast thresholds per NCCN/policyRS ≥15% qualifies; RS ≥5% qualifies if an SF3B1 mutation is present
    Alternate pathwayPatients with RS <15% (or <5% without SF3B1) may qualify if serum EPO ≤ 500 mU/mL

    Permitted Regimens and Dosing

    RegimenIndicationCoverage status
    Combination with a JAK inhibitor (examples: fedratinib, ruxolitinib, momelotinib, pacritinib)
    Myelofibrosis-associated anemia with symptomatic splenomegaly and/or constitutional symptoms; used in combination with a JAK inhibitor as specified
    Covered when used in combination with a JAK inhibitor for myelofibrosis-associated anemia with symptomatic splenomegaly/constitutional symptoms
    RegimenIndicationCoverage status
    Monotherapy per FDA labeling
    Myelofibrosis-associated anemia without splenomegaly or constitutional symptoms (monotherapy per FDA label)
    Covered as monotherapy per FDA labeling for patients without splenomegaly/constitutional symptoms
    RegimenDosing (as studied / per FDA label)IndicationCoverage status
    Subcutaneous luspatercept every 3 weeks
    Starting dose 1.0 mg/kg with possible titration up to 1.75 mg/kg (as in MEDALIST and COMMANDS trials); administered subcutaneously every 3 weeks per FDA labeling
    Lower-risk MDS with symptomatic anemia (ESA‑naive or ESA‑failure depending on subgroup); dosing and titration per trials and FDA label
    Covered when dosed subcutaneously every 3 weeks with starting dose 1.0 mg/kg and titration to 1.75 mg/kg as appropriate per FDA labeling and trial protocols
    RegimenDosing (as studied)IndicationCoverage status
    Subcutaneous luspatercept once every 3 weeks (BELIEVE trial regimen)
    Administered subcutaneously once every 3 weeks for the duration of observed transfusion reduction (as in BELIEVE); trial included adults receiving 6-20 RBC units per 24 weeks with no transfusion-free period >35 days
    Transfusion‑dependent beta thalassemia in adults (meeting trial transfusion criteria)
    Covered when used as in the BELIEVE trial: subcutaneous dosing every 3 weeks for adults meeting transfusion‑dependent criteria

    Policy Revision History

    2026-08-01template_update/clinical_content_updateLatest

    Policy content transferred to a shared policy template; Application section added to state the policy applies to UnitedHealthcare Commercial and Individual Exchange benefit plans; Background, Clinical Evidence, and References updated to reflect current information.

    2026-08-01operational

    Previous policy versions 2025D0084K and IEXD0084.09 were archived.

    Policy Summary
    Payersierra health and life
    PolicyReblozyl (Luspatercept-Aamt) coverage
    Policy CodePolicy 2026D0084L
    Change TypeClinical content and references updatedtemplate and application details revised
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of indication, specialist involvement, dosing per FDA labeling, and evidence of clinical response for continuation requests.
    SourceLink
    On This Page
    Coverage Criteria for Reblozyl (luspatercept-aamt)Coding and Diagnostic ReferencesProvider Requirements, Documentation, and Prior AuthorizationBackground and Clinical ContextDefinitions and Key TermsLine of Therapy and Treatment PositioningBiomarker and Laboratory RequirementsPermitted Regimens and DosingPolicy Revision History
    Source guidanceReferenced in MEDALIST/COMMANDS eligibility considerations and NCCN recommendations
    Thrombocytosis for MDS/MPN — Inv-20
    Thrombocytosis definition for MDS/MPNPlatelet count ≥ 450 x 10^9/L
    Biomarker requirementPresence of SF3B1 mutation plus thrombocytosis required for MDS/MPN overlap initial eligibility
    Clinical contextApplied when diagnosing MDS/MPN with anemia per coverage criteria
    BELIEVE transfusion‑dependence inclusion — Inv-21
    BELIEVE transfusion‑dependence range6–20 RBC units per 24 weeks (trial inclusion criteria)
    Maximum transfusion‑free interval in trialNo transfusion‑free period greater than 35 days during the 24‑week assessment period
    Trial dosing scheduleSubcutaneous luspatercept once every 3 weeks as used in BELIEVE
    MEDALIST/COMMANDS transfusion criteria — Inv-22
    MEDALIST endpointsTransfusion independence for 8 weeks (primary) and 12 weeks (key secondary) during weeks 1–24
    COMMANDS baseline transfusion requirement2–6 PRBC units per 8 weeks for ≥8 weeks pre‑randomization
    COMMON trial dosingLuspatercept administered subcutaneously every 3 weeks (start 1.0 mg/kg, titrate to 1.75 mg/kg for MDS)
  1. HCPCS J0896 may be used for billing reference.
  2. Note

    Clinical pre-assessment — ring sideroblasts and EPO

    For lower‑risk MDS eligibility, document ring sideroblast assessment and a serum erythropoietin (EPO) level as applicable to the diagnostic pathway in the policy.

    • Ring sideroblasts percentage (e.g., ≥15% or <15%; note RS <5% with SF3B1 mutation qualifies in specified subgroups).
    • Serum erythropoietin level (policy uses threshold ≤ 500 mU/mL where applicable).
    Note

    Response evaluation (informational)

    NCCN describes lack of response to luspatercept as failure to achieve a ≥1.5 g/dL hemoglobin rise or failure to decrease RBC transfusion requirement by 6 to 8 weeks; use these criteria to interpret treatment effect though the policy does not mandate a specific step‑therapy algorithm.

    • NCCN defines lack of response as <1.5 g/dL hemoglobin rise or no decrease in transfusion requirement by 6–8 weeks.
    Documentation Required

    Required documentation for initial and renewal requests

    Include documentation that supports the diagnosis, shows specialist involvement, confirms dosing per FDA labeling, and provides evidence of clinical benefit (e.g., reduced transfusion burden or increased hemoglobin) when submitting an authorization request.

    • Supportive diagnostic documentation meeting the policy’s disease‑specific criteria (e.g., transfusion history, IPSS‑R category, SF3B1 status, platelet count where applicable).
    • Record that Reblozyl is prescribed by or in consultation with a hematologist/oncologist or other appropriate specialist.
    • Confirm dosing is in accordance with the FDA‑approved labeling.
    Documentation Required

    Required documentation for continuation

    For continuation/reauthorization, document a positive clinical response to Reblozyl such as a reduction in transfusion burden or an increase in hemoglobin from baseline and indicate the timing of the response relative to treatment.

    • Specify the clinical benefit observed (e.g., number of transfusions avoided, change in units transfused, hemoglobin rise) and the timepoint when measured.
    • Confirm continued prescribing by or consultation with an appropriate specialist and that dosing remains per FDA labeling.
    Denial Risk

    Not covered indications — denial risk

    Requests for Reblozyl to treat alpha thalassemia, beta thalassemia in pediatric patients, non‑transfusion‑dependent beta thalassemia, or sickle beta thalassemia are considered not proven/not medically necessary and may be denied.

    • Alpha thalassemia is listed as not proven/not medically necessary.
    • Beta thalassemia in pediatric patients is listed as not proven/not medically necessary.
    • Non‑transfusion dependent beta thalassemia is listed as not proven/not medically necessary.
    • Sickle beta thalassemia (HbS/beta thalassemia) is listed as not proven/not medically necessary.
    Denial Risk

    Excluded indications — basis for denial

    Requests for Reblozyl for alpha thalassemia, pediatric beta thalassemia, non–transfusion‑dependent beta thalassemia, or sickle beta thalassemia are expressly excluded as not proven/not medically necessary and may be denied.

    • Alpha thalassemia.
    • Beta thalassemia in pediatric patients.
    • Non–transfusion‑dependent beta thalassemia.
    • Sickle beta thalassemia (HbS/beta thalassemia).
    Exclusion notePatients must not have confirmed del(5q)
    Transfusion‑dependent beta thalassemia — Inv-34
    Clinical trial definition (BELIEVE)Participants required 6–20 RBC units per 24 weeks with no transfusion‑free period >35 days
    Indication contextBELIEVE trial population represents transfusion‑dependent adult beta thalassemia used to support efficacy evidence
    Trial dosingSubcutaneous dosing every 3 weeks as in BELIEVE
    Lower‑risk MDS — Inv-35
    IPSS‑R risk categoriesVery low, low, or intermediate per IPSS‑R (referred to as 'lower risk' by FDA and NCCN)
    Associated eligibility featuresRing sideroblast criteria and serum EPO thresholds determine subgroup eligibility
    Clinical applicationApplies to selection of MDS patients for luspatercept per FDA/NCCN-informed policy
    Clinical use
    Used to determine eligibility for luspatercept in lower‑risk MDS populations
    Serum erythropoietin — Inv-40
    Erythropoietin cutoffSerum erythropoietin ≤ 500 mU/mL
    RoleRequired for selection of certain lower‑risk MDS patients with RS below qualifying thresholds
    Referenced inMEDALIST/COMMANDS eligibility language and NCCN guidance